| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
52,209 |
48,507 |
$13.93M |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
42,204 |
36,915 |
$11.42M |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
23,450 |
20,383 |
$1.15M |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
6,147 |
5,926 |
$1.04M |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
5,606 |
5,246 |
$174K |
| 43239 |
Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple |
241 |
165 |
$81K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
319 |
265 |
$77K |
| G0378 |
Hospital observation service, per hour |
138 |
98 |
$60K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
300 |
290 |
$42K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
2,431 |
2,096 |
$37K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
788 |
725 |
$34K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
2,090 |
1,837 |
$32K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
5,521 |
4,680 |
$25K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
163 |
131 |
$24K |
| 43249 |
|
15 |
12 |
$7K |
| 80053 |
Comprehensive metabolic panel |
35,830 |
30,956 |
$3K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
18,021 |
14,776 |
$3K |
| 71045 |
Radiologic examination, chest; single view |
13,313 |
11,374 |
$2K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
1,695 |
1,494 |
$2K |
| 70450 |
Computed tomography, head or brain; without contrast material |
1,350 |
1,136 |
$2K |
| 71046 |
Radiologic examination, chest; 2 views |
4,191 |
3,854 |
$744.83 |
| 85027 |
|
42,632 |
36,827 |
$606.79 |
| 84484 |
|
7,271 |
5,603 |
$366.38 |
| 87070 |
|
751 |
723 |
$365.31 |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
9,333 |
8,578 |
$335.57 |
| 80048 |
Basic metabolic panel (calcium, ionized) |
2,297 |
1,995 |
$306.59 |
| 81001 |
|
17,761 |
15,934 |
$248.23 |
| J7030 |
Infusion, normal saline solution , 1000 cc |
2,662 |
2,459 |
$236.28 |
| 96361 |
Intravenous infusion, hydration; each additional hour |
2,035 |
1,768 |
$233.35 |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
858 |
786 |
$222.64 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
9,642 |
6,820 |
$201.99 |
| 83690 |
|
13,074 |
11,479 |
$188.15 |
| 84703 |
|
1,680 |
1,509 |
$162.00 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
2,372 |
2,201 |
$155.26 |
| 81025 |
|
13,481 |
12,512 |
$97.45 |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
901 |
823 |
$87.88 |
| 87430 |
|
5,724 |
5,517 |
$62.29 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
3,283 |
2,993 |
$61.02 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
285 |
279 |
$43.78 |
| 83880 |
|
629 |
511 |
$35.33 |
| 87081 |
|
3,620 |
3,479 |
$35.04 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
378 |
327 |
$30.25 |
| 85610 |
|
2,340 |
1,945 |
$19.66 |
| 85730 |
|
1,361 |
1,117 |
$17.22 |
| 81003 |
|
7,847 |
7,032 |
$16.50 |
| 83735 |
|
1,002 |
833 |
$15.44 |
| 87420 |
|
245 |
235 |
$13.13 |
| 82248 |
|
272 |
243 |
$5.15 |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
430 |
417 |
$0.00 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
63 |
60 |
$0.00 |
| 82553 |
|
407 |
335 |
$0.00 |
| 94644 |
|
14 |
13 |
$0.00 |
| 36000 |
|
20 |
17 |
$0.00 |
| 85379 |
|
76 |
64 |
$0.00 |
| J1170 |
Injection, hydromorphone, up to 4 mg |
16 |
13 |
$0.00 |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
13 |
12 |
$0.00 |
| 87040 |
|
30 |
24 |
$0.00 |
| 82550 |
|
292 |
246 |
$0.00 |
| C1726 |
Catheter, balloon dilatation, non-vascular |
16 |
13 |
$0.00 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
131 |
111 |
$0.00 |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
62 |
49 |
$0.00 |
| 86901 |
|
26 |
24 |
$0.00 |
| 83605 |
|
12 |
12 |
$0.00 |
| J1630 |
Injection, haloperidol, up to 5 mg |
13 |
12 |
$0.00 |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
15 |
12 |
$0.00 |
| 99053 |
|
671 |
484 |
$0.00 |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
438 |
393 |
$0.00 |
| 84702 |
|
247 |
229 |
$0.00 |
| J2550 |
Injection, promethazine hcl, up to 50 mg |
105 |
96 |
$0.00 |
| G1003 |
Clinical decision support mechanism medicalis, as defined by the medicare appropriate use criteria program |
406 |
337 |
$0.00 |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
114 |
105 |
$0.00 |
| S0119 |
Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) |
42 |
41 |
$0.00 |
| 87186 |
|
13 |
12 |
$0.00 |
| 80076 |
|
14 |
13 |
$0.00 |
| 86900 |
|
26 |
24 |
$0.00 |
| 87210 |
|
13 |
12 |
$0.00 |
| 74018 |
|
25 |
25 |
$0.00 |
| 72125 |
Computed tomography, cervical spine; without contrast material |
45 |
39 |
$0.00 |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
13 |
12 |
$0.00 |